$246.29
0.440.18%
Last update: Oct 28, 12:51 PM
Ascendis Pharma AS
ASNDNASDAQ
Ascendis Pharma (ASND) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Ascendis Pharma (ASND) last issued guidance on January 9, 2026 for fiscal year 2025. The company guided revenue in the range of $838.19M - $838.19M for the period.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.78 | $0.21 | $-0.06 | $-0.41 |
| Actual | $1.05 | $0.32 | $-0.64 | $-1.17 |
| Surprise | +34.6% | +52.4% | -966.7% | -185.1% |
| Revenue | ||||
| Estimate | $353.8M | $318.1M | $289.7M | $248.6M |
| Actual | $394.4M | $288.8M | $288.1M | $249.8M |
| Surprise | +11.5% | -9.21% | -0.55% | +0.46% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $1.13 | $1.40 | $1.43 | $1.98 |
| Revenue | ||||
| Consensus | $417.2M | $465.1M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $1.05 | $0.78 | 34.6 % |
| Q1 | May 7, 2026 | $0.32 | $0.21 | 52.4 % |
| Q4 | Feb 11, 2026 | $-0.64 | $-0.06 | -966.7 % |
| Q3 | Nov 12, 2025 | $-1.17 | $-0.41 | -185.1 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $394.44M | $353.80M | 11.5 % |
| Q1 | May 7, 2026 | $288.77M | $318.05M | -9.21 % |
| Q4 | Feb 11, 2026 | $288.13M | $289.72M | -0.55 % |
| Q3 | Nov 12, 2025 | $249.79M | $248.64M | 0.46 % |
